Bio-Path receives Nasdaq delisting notice for equity non-compliance; plans appeal

BIO-PATH HOLDINGS, INC.

Received Nasdaq delisting letter on Sept 12, 2024 for failing to meet $2.5M stockholders' equity requirement.
Trading suspension set for Sept 23, 2024 unless appeal requested by Sept 19, 2024.
Company intends to request hearing before Nasdaq Hearings Panel to stay suspension.
No assurance that appeal will succeed; stock continues trading under BPTH pending Panel decision.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.